Subscribe to Biotech Blueprint HERE.

While the U.S. gears up for Independence Day, biotech is having its own kind of fireworks. In This Week in Biotech #59, we look at Regeneron landing a major approval for its BCMAxCD3 bispecific; AbbVie making a bold play in in vivo CAR-T; and Argenx entering the macrocyclic peptide race with a $1.5B AI-driven deal.

Meanwhile, RFK Jr. quietly reshapes the vaccine injury landscape, with possible implications for every major COVID vaccine maker.

Also inside:

— China’s first dual GLP-1/GCG agonist approval

— Moderna’s latest win in seasonal flu

— Key updates on ACA coverage, RSV policy, and Alzheimer’s trials